Chimerix Inc. (CMRX) Stock Rating Lowered by Zacks Investment Research
Chimerix Inc. (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
A number of other analysts have also weighed in on the stock. FBR & Co reiterated a “hold” rating on shares of Chimerix in a report on Sunday, October 30th. Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the stock a “buy” rating in a report on Thursday, August 18th. Finally, JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 price objective on shares of Chimerix in a report on Tuesday, August 9th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $8.32.
Chimerix (NASDAQ:CMRX) opened at 4.62 on Wednesday. Chimerix has a 52 week low of $3.50 and a 52 week high of $42.24. The stock’s market cap is $213.51 million. The stock has a 50 day moving average price of $4.80 and a 200-day moving average price of $4.61.
Chimerix (NASDAQ:CMRX) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.02. Chimerix had a negative net margin of 1,451.99% and a negative return on equity of 31.35%. On average, equities analysts anticipate that Chimerix will post ($1.73) EPS for the current fiscal year.
In other news, insider M Michelle Berrey purchased 22,417 shares of Chimerix stock in a transaction that occurred on Monday, August 29th. The stock was bought at an average price of $4.47 per share, with a total value of $100,203.99. Following the completion of the transaction, the insider now directly owns 281,238 shares of the company’s stock, valued at $1,257,133.86. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John M. Leonard sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $5.03, for a total transaction of $25,150.00. The disclosure for this sale can be found here. Corporate insiders own 10.50% of the company’s stock.
Several large investors have recently made changes to their positions in CMRX. Virginia Retirement Systems ET AL purchased a new stake in shares of Chimerix during the second quarter valued at $103,000. Raymond James & Associates increased its stake in shares of Chimerix by 6.9% in the second quarter. Raymond James & Associates now owns 27,083 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,757 shares during the period. Highbridge Capital Management LLC purchased a new stake in shares of Chimerix during the second quarter valued at $112,000. BlackRock Advisors LLC increased its stake in shares of Chimerix by 19.4% in the third quarter. BlackRock Advisors LLC now owns 22,213 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 3,611 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of Chimerix during the second quarter valued at $159,000. 66.25% of the stock is owned by institutional investors.
Chimerix Company Profile
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Receive News & Stock Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related stocks with our FREE daily email newsletter.